Adenovirus vector-based vaccine for infectious diseases

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Chan, J. F., Kok, K., Zhu, Z., Chu, H., To, K. K., Yuan, S., & Yuen, K. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1719902 · Cited by 3,127

Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5

Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt‐Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., & Finberg, R. W. (1997) · Science · doi:10.1126/science.275.5304.1320 · Cited by 3,102

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101544 · Cited by 2,397

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104840 · Cited by 2,259

Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment

Wickham, T. J., Mathias, P., Cheresh, D. A., & Nemerow, G. R. (1993) · Cell · doi:10.1016/0092-8674(93)90231-e · Cited by 2,199

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, A. S., Kovyrshina, A. V., Lubenets, N. L., Grousova, D. M., Erokhova, A. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00234-8 · Cited by 1,747

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713

CGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING.

Ablasser, A., Goldeck, M., Cavlar, T., Deimling, T., Witte, G., Röhl, I., Hopfner, K.-P., Ludwig, J., & Hornung, V. (2013) · Nature · doi:10.1038/nature12306 · Cited by 1,695

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31605-6 · Cited by 1,225

COVID-19 mRNA vaccines: Platforms and current developments

Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308

Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases

Wang, S., Liang, B., Wang, W., Li, L., Feng, N., Zhao, Y., Wang, T., Yan, F., Yang, S., & Xia, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01408-5 · Cited by 230

Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives

Souto, E. B., Blanco-Llamero, C., Krambeck, K., Kiran, N. S., Yashaswini, C., Postwala, H. I., Severino, P. B., Priefer, R., Prajapati, B. G., & Maheshwari, R. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.04.010 · Cited by 184

Two centuries of vaccination: historical and conceptual approach and future perspectives

Montero, D. A., Vidal, R. M., Velasco, J., Carreño, L. J., Torres, J. P., O., M. A. B., Tovar-Rosero, Y.-Y., Oñate, A. A., & O’Ryan, M. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1326154 · Cited by 171

Chitosan-Based Nanomaterial as Immune Adjuvant and Delivery Carrier for Vaccines

Gong, X., Gao, Y., Shu, J., Zhang, C., & Zhao, K. (2022) · Vaccines · doi:10.3390/vaccines10111906 · Cited by 140

Adenoviruses in medicine: innocuous pathogen, predator, or partner

MacNeil, K. M., Dodge, M. J., Evans, A. M., Tessier, T. M., Weinberg, J. B., & Mymryk, J. S. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.10.001 · Cited by 91

Vaccine Strategies to Elicit Mucosal Immunity

Song, Y., Mehl, F., & Zeichner, S. L. (2024) · Vaccines · doi:10.3390/vaccines12020191 · Cited by 87

Oral Vaccines: A Better Future of Immunization

Kwong, K. W.-Y., Xin, Y., Lai, N. C.-Y., Sung, J. C.-C., Wu, K.-C., Hamied, Y. K., Sze, E. T.-P., & Lam, D. M. (2023) · Vaccines · doi:10.3390/vaccines11071232 · Cited by 79

Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history

Kiszel, P., Sík, P. B., Miklós, J., Kajdácsi, E., Sinkovits, G., Cervenak, L., & Prohászka, Z. (2023) · Scientific Reports · doi:10.1038/s41598-023-40103-x · Cited by 72

Nasal vaccines for respiratory infections

Kiyono, H., & Ernst, P. B. (2025) · Nature · doi:10.1038/s41586-025-08910-6 · Cited by 58

Nasal vaccines: solutions for respiratory infectious diseases

Nakahashi-Ouchida, R., Fujihashi, K., Kurashima, Y., Yuki, Y., & Kiyono, H. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.10.009 · Cited by 54

Development of Nasal Vaccines and the Associated Challenges

Nian, X., Zhang, J., Huang, S., Duan, K., Li, X., & Yang, X. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14101983 · Cited by 52

Evolving Horizons: Adenovirus Vectors’ Timeless Influence on Cancer, Gene Therapy and Vaccines

Trivedi, P. D., Byrne, B. J., & Corti, M. (2023) · Viruses · doi:10.3390/v15122378 · Cited by 53

CCHFV vaccine development, current challenges, limitations, and future directions

Ahata, B., & Akçapınar, G. B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1238882 · Cited by 40

Clinical Application of Adenovirus (AdV): A Comprehensive Review

Salauddin, M., Saha, S., Hossain, M. G., Okuda, K., & Shimada, M. (2024) · Viruses · doi:10.3390/v16071094 · Cited by 43

Glycan masking in vaccine design: Targets, immunogens and applications

Martina, C. E., Crowe, J. E., & Meiler, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1126034 · Cited by 36

Swine influenza A virus: challenges and novel vaccine strategies

Petro-Turnquist, E. M., Pekarek, M. J., & Weaver, E. A. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1336013 · Cited by 34

Advances of Recombinant Adenoviral Vectors in Preclinical and Clinical Applications

Scarsella, L., Ehrke‐Schulz, E., Paulussen, M., Thal, S. C., Ehrhardt, A., & Aydin, M. (2024) · Viruses · doi:10.3390/v16030377 · Cited by 25

Cancer mRNA vaccines: clinical application progress and challenges

Li, H., Min, L., Du, H., Wei, X., & Tong, A. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217752 · Cited by 26

Current Advances in Viral Nanoparticles for Biomedicine

Sun, X., Tian, T., Lian, Y., & Cui, Z. (2024) · ACS Nano · doi:10.1021/acsnano.4c13146 · Cited by 21

Identification of Inhibitors and Drug Targets for Human Adenovirus Infections

Liu, M., Jiang, L., Cao, W., Wu, J., & Chen, X. (2022) · Viruses · doi:10.3390/v14050959 · Cited by 19

A China-developed adenovirus vector-based COVID-19 vaccine: review of the development and application of Ad5-nCov

Wang, S., Liu, W.-Q., Li, Y., Li, J., & Zhu, F. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2242528 · Cited by 18

Novel technologies are turning a dream into reality: conditionally replicating viruses as vaccines

Tang, Y., Yu, C., & Cai, X. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.09.002 · Cited by 20

Progress in African Swine Fever Vector Vaccine Development

Yang, Y., Yuan, H., Zhang, Y., Luan, J., & Wang, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26030921 · Cited by 18

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines

Cohen, G., Jungsomsri, P., Sangwongwanich, J., Tawinprai, K., Siripongboonsitti, T., Porntharukchareon, T., Wittayasak, K., Thonwirak, N., Soonklang, K., Sornsamdang, G., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2052525 · Cited by 17

Adenovirus-Based Gene Therapy for Bone Regeneration: A Comparative Analysis of In Vivo and Ex Vivo BMP2 Gene Delivery

Bukharova, T. B., Nedorubova, I. A., Mokrousova, V., Meglei, A. Y., Basina, V. P., Nedorubov, A. A., Vasilyev, A. V., Grigoriev, T. E., Zagoskin, Y. D., Чвалун, С. Н., et al. (2023) · Cells · doi:10.3390/cells12131762 · Cited by 17

In vivo mRNA expression of a multi-mechanistic mAb combination protects against Staphylococcus aureus infection

Tkaczyk, C., Newton, M. R., Patnaik, M. M., Thom, G., Strain, M., Gamson, A., Daramola, O., Murthy, A., Douthwaite, J. A., Stepanov, O., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.036 · Cited by 18

Vaccine formulation design: challenges and opportunities

Zafar, S., Akhtar, A., Sayed, E., Onaiwu, E., Arshad, M. S., & Ahmad, Z. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00017c · Cited by 17

Guillain-Barré syndrome and COVID-19 vaccines: focus on adenoviral vectors

Rzymski, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1183258 · Cited by 16

DEC-205 receptor targeted poly(lactic-co-glycolic acid) nanoparticles containing Eucommia ulmoides polysaccharide enhances the immune response of foot-and-mouth disease vaccine in mice

Feng, Y., Fan, J., Wu, D., Liu, Q., Li, H., Zhang, X., Li, S., Tang, F. R., Liu, Z., Zhang, L., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.12.158 · Cited by 15

Revolutionizing antiviral therapy with nanobodies: Generation and prospects

Mustafa, M. I., & Mohammed, A. (2023) · Biotechnology Reports · doi:10.1016/j.btre.2023.e00803 · Cited by 14

Developing an efficient MGCR microneedle nanovaccine patch for eliciting Th 1 cellular response against the SARS-CoV-2 infection

Gao, A., Chen, Y., Liang, H., Cui, X., Zhang, A., & Cui, D. (2023) · Theranostics · doi:10.7150/thno.83390 · Cited by 14

From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2

Kumar, A., Tripathi, P., Kumar, P., Shekhar, R., & Pathak, R. (2024) · Vaccines · doi:10.3390/vaccines12050459 · Cited by 17

Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial

Tawinprai, K., Siripongboonsitti, T., Porntharukchareon, T., Wittayasak, K., Thonwirak, N., Soonklang, K., Sornsamdang, G., Auewarakul, C. U., & Mahanonda, N. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.019 · Cited by 14

Mucosal Vaccination: A Promising Alternative Against Flaviviruses

Lurı́a-Pérez, R., Sánchez-Vargas, L. A., Muñoz-López, P., & Mellado‐Sánchez, G. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.887729 · Cited by 13

Oral mucosa immunity: ultimate strategy to stop spreading of pandemic viruses

Jang, H., Matsuoka, M., & Freire, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1220610 · Cited by 13

Vaccine Development for Human Leishmaniasis

Clímaco, M. D. C., Kraemer, L. R., & Fujiwara, R. T. (2023) · Springer eBooks · doi:10.1007/978-3-031-24355-4_14 · Cited by 13

mRNA vaccines: a transformative technology with applications beyond COVID ‐19

Overmars, I., Au‐Yeung, G., Nolan, T. M., & Steer, A. C. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51620 · Cited by 12

Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets

Khan, S., Salisch, N. C., Gil, A. I., Boedhoe, S., Boer, K. F.-D., Serroyen, J., Schuitemaker, H., & Zahn, R. C. (2022) · npj Vaccines · doi:10.1038/s41541-022-00567-w · Cited by 14

Pharmaceutical strategies for optimized mRNA expression

Shi, Y., Mao, J., Wang, S., Ma, S., Luo, L., & You, J. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122853 · Cited by 11

Adenoviral Vectors for Gene Therapy of Hereditary Diseases

Muravyeva, A., & Smirnikhina, S. (2024) · Biology · doi:10.3390/biology13121052 · Cited by 11

Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics

Farhad, T., Neves, K., Arbuthnot, P. B., & Maepa, M. B. (2022) · Genes · doi:10.3390/genes13111941 · Cited by 11

Liver Transaminases in Pediatric Adenovirus Infection—A Five-Year Study in Two Major Reference Centers from Romania

Săndulescu, O., Streinu-Cercel, A., Miron, V. D., Covăcescu, M., Streinu‐Cercel, A., & Craiu, M. (2023) · Microorganisms · doi:10.3390/microorganisms11020302 · Cited by 9

Time trend of respiratory viruses before and during the COVID‐19 pandemic in severe acute respiratory virus infection in the Sultanate of Oman between 2017 and 2022

Kindi, H. A., Meredith, L. W., Al‐Jardani, A., Sajina, F., Al-Shukri, I., al Haj, R., Alyaquobi, F., Wahaibi, A. S. A., & Al-Maani, A. S. (2023) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13233 · Cited by 9

SARS-CoV-2 Vaccination and the Multi-Hit Hypothesis of Oncogenesis

Angues, R. V., & Bustos, Y. P. (2023) · Cureus · doi:10.7759/cureus.50703 · Cited by 11

COVID-19 Vaccines in Children

Fayad, D., & Frenck, R. W. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010087 · Cited by 11

Development of a perfusion process for serum-free adenovirus vector herpes zoster vaccine production

Sun, Y., Huang, L., Nie, J., Feng, K., Liu, Y., & Bai, Z. (2022) · AMB Express · doi:10.1186/s13568-022-01398-7 · Cited by 8

Integrating Affinity Chromatography in the Platform Process for Adenovirus Purification

Wu, Y., Barbieri, E., Smith, W. K., Minzoni, A., Kilgore, R., Chu, W., Daniele, M. A.-A., & Menegatti, S. (2025) · Biotechnology and Bioengineering · doi:10.1002/bit.29006 · Cited by 7

Innovative translational platforms for rapid developing clinical vaccines against COVID‐19 and other infectious disease

Wang, N., & Wang, T. (2024) · Biotechnology Journal · doi:10.1002/biot.202300658 · Cited by 11

Self-Adjuvanting Adenoviral Nanovaccine for Effective T-Cell-Mediated Immunity and Long-Lasting Memory Cell Activation against Tuberculosis

Sowndharya, C. K., Mehnath, S., Ponbharathi, A., & Jeyaraj, M. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00619 · Cited by 8

Monkeypox outbreak: after COVID-19, another challenge for the hemostatic system?

Marietta, M., Coluccio, V., & Luppi, M. (2022) · Internal and Emergency Medicine · doi:10.1007/s11739-022-03112-8 · Cited by 7

One HA stalk topping multiple heads as a novel influenza vaccine

Zhou, P., Qiu, T., Wang, X., Yang, X., Shi, H., Zhu, C., Dai, W., Xing, M., Zhang, X., Xu, J., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2290838 · Cited by 7

HEHR: Homing Endonuclease-Mediated Homologous Recombination for Efficient Adenovirus Genome Engineering

Schröer, K., Arakrak, F., Bremke, A., Ehrhardt, A., & Zhang, W.-L. (2022) · Genes · doi:10.3390/genes13112129 · Cited by 4

Looking beyond the origin of SARS-CoV-2: Significant strategic aspects during the five-year journey of COVID-19 vaccine development

Chakraborty, C., Lo, Y.-H., Bhattacharya, M., Das, A., & Wen, Z. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102527 · Cited by 8

Development of oncolytic and gene therapy vectors based on adenovirus serotype 4 as an alternative to adenovirus serotype 5

Sallard, E., Schulte, L., van den Boom, A., Klimovitskii, A. E., Knierer, J., Hagedorn, C., Knocks, M., Zhang, W., Kreppel, F., Ehrhardt, A., et al. (2023) · The Journal of Gene Medicine · doi:10.1002/jgm.3576 · Cited by 6

Recent Advances in Vaccine Adjuvants: From Lab to Clinic

Vardikar, A., Prajapati, M. K., Gholap, A. D., Rojekar, S. V., Keshari, R., Jain, H., & Rajput, A. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126180 · Cited by 5

Gene therapies for osteoarthritis: progress and prospects

Defois, A., Bon, N., Mével, M., Deniaud, D., Maugars, Y., Guicheux, J., Adjali, O., & Vinatier, C. S. (2024) · Journal of Cartilage & Joint Preservation · doi:10.1016/j.jcjp.2024.100186 · Cited by 6

ADEVO: Proof-of-concept of adenovirus-directed EVOlution by random peptide display on the fiber knob

Sallard, E., Fischer, J., Schröer, K., Dawson, L.-M., Beaude, N., Affes, A., Ehrke‐Schulz, E., Zhang, W., Westhaus, A., Cabanes‐Creus, M., et al. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200867 · Cited by 5

Adenovirus type 34 and HVR1-deleted Adenovirus type 5 do not bind to PF4: clearing the path towards vectors without thrombosis riskPreprint

Sallard, E., Pembaur, D., Schröer, K., Schellhorn, S., Koukou, G., Schmidt, N., Zhang, W., Kreppel, F., & Ehrhardt, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.07.515483 · Cited by 5

Engineering immune cells for next-generation therapies

Han, M., Lou, J., Pan, M., Xu, S., Jiang, X., & Jing, W. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115012 · Cited by 4

Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5

Onishi, R., Ikemoto, S., Shiota, A., Tsukamoto, T., Asayama, A., Tachibana, M., Sakurai, F., & Mizuguchi, H. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124480 · Cited by 4

Pooled Analysis of the Effect of Pre-Existing Ad5 Neutralizing Antibodies on the Immunogenicity of Adenovirus Type 5 Vector-Based COVID-19 Vaccine from Eight Clinical Trials

Liu, W., Li, Y., Li, X., Wang, F., Qi, R., Zhu, T., & Li, J. (2025) · Vaccines · doi:10.3390/vaccines13030333 · Cited by 4

Ad5-nCoV Vaccination Could Induce HLA-E Restricted CD8+ T Cell Responses Specific for Epitopes on Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein

Wang, Y., Yang, L., Tang, K., Zhang, Y., Zhang, C., Zhang, Y., Jin, B., Zhang, Y., Zhuang, R., & Ma, Y. (2023) · Viruses · doi:10.3390/v16010052 · Cited by 5

Regulation of protein thermal stability and its potential application in the development of thermo-attenuated vaccines

Wang, M., Wu, C., Liu, N., Jiang, X., Dong, H., Zhao, S., Li, C., Xu, S., & Gu, L. (2024) · Engineering Microbiology · doi:10.1016/j.engmic.2024.100162 · Cited by 4

Effects of Common Anti-Inflammatories on Adenovirus Entry and Their Physicochemical Properties: An In-Depth Study Using Cellular and Animal Models

Galván‐Salazar, H. R., Delgado‐Machuca, M., Hernández‐Fuentes, G. A., Aurelien-Cabezas, N. S., Rodríguez‐Hernández, A., Veloz, I. G., Mendoza-Hernandez, M. A., Martínez‐Fierro, M. L., Zaizar-Fregoso, S. A., Rodriguez-Sanchez, I. P., et al. (2024) · Microbiology Research · doi:10.3390/microbiolres15030105 · Cited by 4

How well do different COVID-19 vaccines protect against different viral variants? A systematic review and meta-analysis

Hoang, T. N. A., Byrne, A., Quach, H., Bannister-Tyrrell, M., & VOGT, F. M. (2024) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/trae082 · Cited by 6

Single-Dose Intranasal or Intramuscular Administration of Simian Adenovirus-Based H1N1 Vaccine Induces a Robust Humoral Response and Complete Protection in Mice

Voronina, D. V., Викторовна, В. И., Zubkova, O. V., Ozharovskaia, T. A., Popova, O. D., Chugunova, A. S., Павловна, Г. П., Игоревич, З. Д., Savina, D. M., Favorskaya, I. A., et al. (2025) · Viruses · doi:10.3390/v17081085 · Cited by 3

Method validation and assessment of the biodistribution and shedding for adenovirus vector-based vaccine using qPCR and dPCR

Tanaka, Y., Hamano, S., Ishii‐Watabe, A., Saito, Y., & Kikura‐Hanajiri, R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101549 · Cited by 3

Heterologous DNA–Adenovirus Prime–Boost Strategy Expressing Bluetongue Virus VP2 and VP7 Proteins Protects Against Virulent Challenge

Nogales‐Altozano, P., Gómez‐Marcos, L., Carlón, A. B., Louloudes-Lázaro, A., Rivera-Rodríguez, A., Larraga, J., Alcolea, P. J., Alonso, A., Larraga, V., Martı́n, V., et al. (2025) · Vaccines · doi:10.3390/vaccines13090991 · Cited by 3

Comprehensive review on COVID-19: etiology, pathogenicity, and treatment

Zawily, A. E., Eckert, S., Adajar, R. C., Wagih, N., Elmaidomy, A. H., Helmy, A. M., Mustafa, M., Elshorbagi, M., Ghali, E., Fadl, R. G., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1569013 · Cited by 4

Microneedles Based Thermally Stable Ad‐5 Viral Vector for Vaccine Delivery

Singh, P., Sharma, N., Huang, F., Bhaskar, N., Akbaba, H., Park, J., Radhakrishnan, A., Sakhrie, A., Nguyen, L., Ge, G., et al. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202504342 · Cited by 3

Mucosal immunity and vaccine development

Hong, W., Alu, A., Zhang, Z., Zhang, Y. L., He, X., Xu, L., Li, M., He, W., & Wang, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02687-4 · Cited by 3

A universal recombinant adenovirus type 5 vector-based COVID-19 vaccine

Li, X., Peng, Q., Liu, X., Xu, H., Liu, J., Wu, X., Ye, Q., Li, M., & Li, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1374486 · Cited by 3

Oral Ad5 Vector‐Based SARS‐CoV‐2 Vaccine Effectively Induces Mucosal and Systemic Immune Responses in BALB/c Mice

Mao, T., Zhang, P., Jiang, S., Li, D.-D., Li, J., Zhang, Q., Wang, H., Kong, X., & Duan, Z. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70236 · Cited by 3

A Critical Assessment of COVID-19 Genomic Vaccines

Sabbah, D. A., Hajjo, R., & Sunoqrot, S. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230825094341 · Cited by 4

HeterologousPrime-Boost immunizationwithAdenoviral vector and recombinant subunit vaccines strategies against dengue virus type2

Shoushtari, M. M., Salehi-Vaziri, ‪., Kadkhodazadeh, M., Teimoori, A., Arashkia, A., Roohvand, F., Teimoori‐Toolabi, L., Pouriayevali, M. H., & Azadmanesh, K. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114032 · Cited by 3

Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial

Tica, J., Rezelj, V. V., Baron, B., van Paassen, V., Zaidman, J., Fairlie, L., Scheper, G. C., Gars, M. L., Struyf, F., Douoguih, M., et al. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2450120 · Cited by 3

LAVR-289, an Orally Bioavailable Inhibitor of Adenovirus Replication In Vitro and In Vivo

Quentin-Froignant, C., Tollefson, A. E., Cline-Smith, A., Kappler‐Gratias, S., Landrein, N., Roy, V., Agrofoglio, L. A., Tóth, K., Wodrich, H., & Gallardo, F. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00170 · Cited by 3

Genetically Mediated Cell Membrane Engineering Strategies and Their Scope in Biomedical Applications

Tollabi, M., Kheirandish, M. H., Mehrabi, A., Poursalehi, Z., Heidari, M., & Milan, P. B. (2025) · Springer eBooks · doi:10.1007/978-3-031-93425-4_6 · Cited by 2

Development and immunogenicity of adenoviral Fc-fused FMDV virus-like particle vaccine in swine

Park, J., Lee, H., Kang, K.-J., Jung, M. K., Mun, J. Y., Kim, M., Pyun, J., Hwang, S. Y., Park, J.-H., & Shin, H.-J. (2025) · Veterinary Quarterly · doi:10.1080/01652176.2025.2564443 · Cited by 2

The path from early- to late-liver stage arresting genetically attenuated parasites as a malaria vaccination strategy

Lamers, O. A. C., Franke-Fayard, B. M. D., Roestenberg, M., & Krol, J. M. M. (2025) · npj Vaccines · doi:10.1038/s41541-025-01265-z · Cited by 2

Application of biomimetic approaches in the treatment of neurological disorders

Sun, J., Li, H., Wang, J., & Yang, W. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102334 · Cited by 3

Enhancing the breadth of protection in mice with a multivalent influenza vaccine

Wang, X., Niu, Y., Hu, Y., Zhu, C., Yang, X., Shi, H., Yan, Y., Zhou, P., Ding, L., Zhang, M., et al. (2026) · Communications Biology · doi:10.1038/s42003-025-09451-4 · Cited by 2

Incubation Temperature and Period During Denarase Treatment and Microfiltration Affect the Yield of Recombinant Adenoviral Vectors During Downstream Processing

Sonugür, F. G., Babahan, C., Abgarmi, S. A., & Akbulut, H. (2022) · Molecular Biotechnology · doi:10.1007/s12033-022-00616-8 · Cited by 2

A Novel Vaccine Strategy to Prevent Cytauxzoonosis in Domestic Cats

Weerarathne, P., Maker, R., Huang, C., Taylor, B., Cowan, S. R., Hyatt, J., Selvan, M. T., Shatnawi, S., Thomas, J. E., Meinkoth, J. H., et al. (2023) · Vaccines · doi:10.3390/vaccines11030573 · Cited by 2

Recent Advancement of Microneedle Technique in Diagnosis and Therapy of Diseases

Kanugo, A. (2023) · International Journal of Pharmaceutical Sciences and Nanotechnology · doi:10.37285/ijpsn.2023.16.4.8 · Cited by 2

Longitudinal multiomic profiling and corticosteroid modulation of the immediate innate immune response to an adenovirus-vector vaccine

Choi, S. J., Lee, W., Kim, S. C., Jo, H.-Y., Park, H., Kim, H. B., Park, W., Park, S. H., Ko, J., & Lee, J. S. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.07.019 · Cited by 2

FastAd: A versatile toolkit for rapid generation of single adenoviruses or diverse adenoviral vector libraries

Lu, S., Lee, Y.-Y., Andres, F. G. M., Moyer, D. A., & Barry, M. A. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101356 · Cited by 2

Achievement of maximal SARS-CoV-2 collective immunity among the Tajik population by March 2022

Popova, A. Y., Смирнов, В. С., Egorova, S. A., Abdullozoda, J. A., Мехмондустович, Р. М., Milichkina, A. M., Ivanov, V. A., Д., В. С., Ramsay, E. S., Mullodzhanova, M. M., et al. (2023) · Medical Immunology (Russia) · doi:10.15789/1563-0625-aom-2630 · Cited by 2

Confronting Inequalities and Bridging the Divide: A Retrospective Study Assessment of Country-Level COVID-19 Vaccine Equality with a Cox Regression Model

Cheng, L., Chan, W. K., Lijie, Z., Chao, M. H., & Wang, Y. (2024) · Vaccines · doi:10.3390/vaccines12050552 · Cited by 3

Dendritic cell targeting in lymph nodes with engineered modular adapters improves HAdV5 and HC-HAdV5 tumor vaccination by co-secretion of IL-2v and IL-21Preprint

Weiss, F., Kolibius, J., Freitag, P. C., Gantenbein, F., Kipar, A., & Plückthun, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.27.591433 · Cited by 2

Manufacturing and Control of Viral‐Vector Vaccines

Chavda, V. P., Vaghela, D. A., Barman, D., Newar, A., & Ahmed, N. (2025) · doi:10.1002/9781394271566.ch8 · Cited by 2

Ferritin nanoparticle complex with porcine epidemic diarrhea virus spike protein induces neutralizing antibody response against PEDV in mouse models

Tennakoon, M. S. B. W. T. M. N. S., Park, J., Lee, H., Ryu, J.-H., & Shin, H. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107509 · Cited by 1

Adenovirus-Based Single-Dose Vaccines for SARS-CoV-2: A Review

Chavda, V. P., Mehta, A. A., Zafar, H., Raza, F., Paiva‐Santos, A. C., Balar, P. C., Apostolopoulos, V., & Vora, L. K. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl25094 · Cited by 2

A recombinant lipidated receptor-binding domain is a promising self-adjuvanting antigen for mucosal vaccine

Xu, H., Wang, T., Zhang, Y., Wang, H., Yu, S., Hou, X., Zhang, B., Sun, P., Wu, J., & Liu, B. (2025) · Glycoscience & Therapy · doi:10.1016/j.glycos.2025.100019 · Cited by 1

The role of TgEfhc3 in Toxoplasma gondii biology and its prospects as a subunit vaccine

Tian, X., Ma, H., Wang, Q., Zhu, B., Li, Y., Zhang, J., Wang, J., Hu, Y., Li, Y., Zhang, Z., et al. (2026) · Parasites & Vectors · doi:10.1186/s13071-026-07274-8 · Cited by 1

First Isolation and Identification of Homologous Recombination Events of Porcine Adenovirus from Wild Boar

Oba, M., Borjigin, S., Kikuchi, F., Oi, T., Takemae, H., Ishida, H., Murakami, H., Aihara, N., Shiga, T., Kamiie, J., et al. (2022) · Viruses · doi:10.3390/v14112400 · Cited by 1

Mucosal immune probiotic vector vaccines: Development and prospects for application in COVID-19

Zha, R., Yi, B., Liao, C., Li, X., & Lu, J. (2023) · One Health Bulletin · doi:10.4103/2773-0344.387693 · Cited by 1

Construction of recombinant adenovirus-5 vector to prevent replication-competent adenovirus occurrence

Xie, W., Yuan, Y., Liu, B., & Liang, M. (2023) · Acta Virologica · doi:10.3389/av.2023.11642 · Cited by 1

Effect of silencing SSB1 gene on the expression of NBS1 in irradiated rat submandibular gland cells

Gao, L., Lv, Q., Huang, Y., Fan, Y., Zhao, L., Zhao, Y., Wang, X., Mo, D., Lu, H., & Wang, D. (2024) · Cellular and Molecular Biology · doi:10.14715/cmb/2024.70.1.15 · Cited by 1

Modeling comorbidity of depression and anxiety in rats

Chkhetiani, M. (2008) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2008.05.187

Adenoviral Vector Immunity: Its Implications and Circumvention Strategies

S. Ahi, Y., S. Bangari, D., & K. Mittal, S. (2011) · Current Gene Therapy · doi:10.2174/156652311796150372 · Cited by 185

Adenovirus Vectors: Excellent Tools for Vaccine Development

Chang, J. (2021) · Immune Network · doi:10.4110/in.2021.21.e6 · Cited by 129

Engineered adenovirus serotypes for overcoming anti-vector immunity

Dharmapuri, S., Peruzzi, D., & Aurisicchio, L. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903187053 · Cited by 38

Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.

Hartman, Z. C., Appledorn, D. M., & Amalfitano, A. (2008) · Virus Research · doi:10.1016/j.virusres.2007.10.005 · Cited by 239